The Private Equity Catalyst: Reshaping the Generics and Biosimilar Industry
Why the Generics and Biosimilar Market is Redefining Private Equity Success For years, the generics and biosimilar industries have been defined by stability and volume—a reliable but low-margin foundation. Today, Private Equity (PE) is transforming this narrative, moving beyond traditional financial engineering to become a primary force for operational excellence and unprecedented value creation. This
The Private Equity Catalyst: Reshaping the Generics and Biosimilar Industry Read More »